Yazar "Eren, Gullu" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics
    (Taylor & Francis Ltd, 2022) Ataseven, Arzu; Temiz, Selami Aykut; Eren, Gullu; Ozer, Ilkay; Dursun, Recep
    Background Biological agent treatments represent a relatively new field and their effects on routine laboratory parameters are not fully known as there has been little research in the area. In our study, we aimed to evaluate the differences between the two main biological treatment groups and their effects on routine laboratory parameters. Methods Patients were enrolled when they had received treatment for more than six months with biological treatments between January 2013 and April 2020. The available data on routine laboratory parameters were collected by routine blood tests before the treatment, at three months, and at the final evaluation. Results When the changes in routine laboratory parameters were evaluated by treatment, it was found that the NLR and CRP values decreased statistically significantly in the anti-TNF group compared to the IL inhibitor group. In addition, strong suppression of these inflammation parameters means strong suppression of the immune system response. In addition, AST, ALT, and creatinine values were found to be statistically significantly higher in the anti-TNF group compared to the IL inhibitor group. Conclusions In our study, anti-TNF treatments are shown to be more effective in reducing inflammation parameters while IL antagonists are safer in terms of biochemical parameters.
  • Küçük Resim Yok
    Öğe
    The Platelet/Lymphocyte Ratio in Patients with Ischemic Stroke Treated with Intravenous Thrombolysis and Its Relationship with Mortality, Disability, and Prognosis
    (Galenos Publ House, 2021) Eren, Fettah; Demir, Aysegul; Eren, Gullu
    Introduction: The platelet/lymphocyte ratio (PLR) has been studied frequently to determine the prognosis of cardiovascular diseases, chronic inflammatory diseases, and malignancies. Particularly, the PLR is an indicator of systemic inflammation and atherosclerosis. In this study, we aimed to evaluate the value of the PLR and its relationship with mortality, cerebral hemorrhagic transformation, and short-term prognosis in patients with stroke treated with intravenous thrombolysis. Methods: Two hundred fifty stroke patients treated with intravenous thrombolysis were included in the study. Initial symptoms, comorbidities, and localization of cerebral ischemia were recorded. Disability was scored on the National Institutes of Health (NIH) stroke scale. At the 24Th and 72nd hours after treatment, hemorrhagic transformation was evaluated by brain computed tomography. The in-hospital mortality rate was calculated. Patients were divided into groups according to the difference in the NIH stroke scale (between admission and discharge). Serum platelet and lymphocyte levels and PLR values were determined. Results: There were 128 (51.2%) female and 122 (48.8%) male patients included in the study. Their mean age was 71.88 +/- 12.36 years. The lymphocyte count was low and the PLR was high in patients with a high level of initial disability (p<0.01). The lymphocyte count was higher in patients with clinical improvement (p=0.023). The lymphocyte count was lower and the PLR was higher in patients who died (p<0.01). The platelet level was lower in patients with hemorrhagic transformation (p=0.024). The lymphocyte level and PLR were similar in the hemorrhagic transformation groups (p=0.156, p=0.675). Conclusion: In this study, it was determined that mortality is related to the PLR, and hemorrhagic transformation is related to platelet levels in patients with ischemic stroke treated with intravenous thrombolysis.